@article{Wu2025, 
author = {Shuai Wu and Li Zhu and Sheng Ni and Xiong Zhao and Meng Yan and Yuan Zhong and Karissa Kusuma and Yi Liang and Kaiwen Bao and Kai Qu and Xian Qin and Kun Zhang and Wuquan Deng and Da Sun and Wei Wu},
title = {Hemoglobin integrated red blood cell membrane-coated metal-organic framework nano-platform for improving the self-adaptive blood glucose management},
year = {2025},
journal = {Nano Research},
volume = {18},
number = {1},
pages = {94907078},
keywords = {metal-organic frameworks, glucose-responsive, glucose oxidase, hemoglobin, red blood cell membrane, insulin delivery},
url = {https://www.sciopen.com/article/10.26599/NR.2025.94907078},
doi = {10.26599/NR.2025.94907078},
abstract = {Diabetes, a prevalent chronic metabolic disorder, often leads to severe complications. Currently, existing treatment methods may pose life-threatening risks due to poor patient compliance and inaccurate dosing of subcutaneous insulin injections. Hence, a biomimetic red blood cell (RBC) membrane-coated glucose-responsive nanoplatform is developed for controlling insulin release. Functionalizing nanoplatforms with RBC membrane can prolong the half-life of nano-formulation in vivo mediated by the biomimetic immune escape. Simultaneously, the cascade catalytic effect of glucose oxidase (GOx) encapsulated in metal-organic frameworks (MOFs) and hemoglobin (Hb) in the RBC membrane are able to not only facilitate glucose-responsive insulin release, but also eliminate the detrimental by-product hydrogen peroxide (H2O2) resulting from the Hb mediated H2O2 scavenging. Both in vitro and in vivo studies have demonstrated the favorable glucose-responsive performances of this advanced nano-platform with a single intravenous injection maintaining blood glucose balance in Type 1 Diabetes (T1D) mice for an extended duration without the hypoglycemia risk. Therefore, this biomimetic insulin delivery system is poised to function as a strategy for the intravenous insulin administration, offering a promising drug candidate for the self-adaptive long-term T1D treatment.}
}